{"id":"https://openalex.org/W2549915482","doi":null,"title":"Hepatic a Typical PKC: A Novel Target for Newlydevelpoed Inhibitors that Reverse Obesity and Metabolic Syndrome and Diabetic Characteristics and Features in Human Hepatocytes and a Murine Obesity/Diabetes Model","display_name":"Hepatic a Typical PKC: A Novel Target for Newlydevelpoed Inhibitors that Reverse Obesity and Metabolic Syndrome and Diabetic Characteristics and Features in Human Hepatocytes and a Murine Obesity/Diabetes Model","alternate_titles":[],"publication_year":2013,"publication_date":"2013-06-19","ids":{"openalex":"https://openalex.org/W2549915482","mag":"2549915482"},"language":"en","primary_location":{"id":"mag:2549915482","doi":null,"is_oa":false,"landing_page_url":"https://www.omicsonline.org/proceedings/hepatic-a-typical-pkc-a-novel-target-for-newlydevelpoed-inhibitors-that-reverse-obesity-and-metabolic-syndrome-and-diabetic-characteristics-and-featur-3023.html","pdf_url":null,"source":{"id":"https://openalex.org/S2764521035","display_name":"Pharmaceutica Analytica Acta","issn_l":"2153-2435","issn":["2153-2435"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Pharmaceutica Analytica Acta","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2549915482"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101971265","display_name":"Robert V. Farese","orcid":"https://orcid.org/0000-0003-3711-1452","observed_orcids":["https://orcid.org/0000-0003-3711-1452"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Robert V. Farese","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5101971265"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.638700008392334,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.638700008392334,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.08500000089406967,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.060100000351667404,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/protein-kinase-c","display_name":"protein kinase C","score":0.652999997138977},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9160000085830688},{"id":"https://openalex.org/keywords/hepatic-insulin-resistance","display_name":"hepatic insulin resistance","score":0.8450000286102295},{"id":"https://openalex.org/keywords/srebp-1c","display_name":"SREBP-1c","score":0.8930000066757202},{"id":"https://openalex.org/keywords/lipogenesis","display_name":"lipogenesis","score":0.7889999747276306},{"id":"https://openalex.org/keywords/gluconeogenesis","display_name":"gluconeogenesis","score":0.9580000042915344},{"id":"https://openalex.org/keywords/irs2","display_name":"insulin receptor substrate 2","score":0.7350000143051147},{"id":"https://openalex.org/keywords/akt2","display_name":"AKT2","score":0.8830000162124634},{"id":"https://openalex.org/keywords/hepatic-steatosis","display_name":"hepatic steatosis","score":0.8410000205039978},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.6869999766349792},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.8289999961853027},{"id":"https://openalex.org/keywords/hypertriglyceridemia","display_name":"hypertriglyceridemia","score":0.8199999928474426},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.9750000238418579},{"id":"https://openalex.org/keywords/impaired-glucose-tolerance","display_name":"impaired glucose tolerance","score":0.8410000205039978},{"id":"https://openalex.org/keywords/insulin-signaling","display_name":"insulin signaling","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.8146268129348755},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7739606499671936},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.6949028968811035},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.6489992141723633},{"id":"https://openalex.org/C112446052","wikidata":"https://www.wikidata.org/wiki/Q422579","display_name":"Insulin receptor","level":4,"score":0.47645023465156555},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.46106964349746704},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4589582085609436},{"id":"https://openalex.org/C195794163","wikidata":"https://www.wikidata.org/wiki/Q420877","display_name":"Protein kinase C","level":3,"score":0.45166897773742676},{"id":"https://openalex.org/C185967709","wikidata":"https://www.wikidata.org/wiki/Q101433828","display_name":"Insulin receptor substrate","level":5,"score":0.45033860206604004},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.44319018721580505},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.28931933641433716},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.25409120321273804},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.19828498363494873},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12273058295249939}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2549915482","doi":null,"is_oa":false,"landing_page_url":"https://www.omicsonline.org/proceedings/hepatic-a-typical-pkc-a-novel-target-for-newlydevelpoed-inhibitors-that-reverse-obesity-and-metabolic-syndrome-and-diabetic-characteristics-and-featur-3023.html","pdf_url":null,"source":{"id":"https://openalex.org/S2764521035","display_name":"Pharmaceutica Analytica Acta","issn_l":"2153-2435","issn":["2153-2435"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Pharmaceutica Analytica Acta","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1965492178","https://openalex.org/W2171919261","https://openalex.org/W3135873083","https://openalex.org/W2034875063","https://openalex.org/W6908457576","https://openalex.org/W2097987102","https://openalex.org/W2060782125","https://openalex.org/W2144032621","https://openalex.org/W1982810858","https://openalex.org/W2147359359"],"abstract_inverted_index":{"Results:":[0],"Opposite":[1],"to":[2],"PKC-\u03b9":[3,11,56],"deficiency":[4],"in":[5,14,71,104,118,131],"muscle,":[6],"which":[7],"limits":[8],"glucose":[9,137],"transport,":[10],"was":[12,69],"over-expressed/over-active":[13],"hepatocytes":[15,86],"of":[16,24,49,84,97,121],"T2DM":[17,73,85,108],"humans,":[18],"and":[19,34,36,45,81,95,100,116,124,133,143],"accompanied":[20],"by":[21,58],"increased":[22,54],"expression":[23,57,96,120],"sterol":[25],"receptor":[26,51],"element":[27],"binding":[28],"protein-1c":[29],"(SREBP-1),":[30],"SREBP1c-dependent":[31],"lipogenic":[32],"enzymes,":[33,126],"proinflammatory":[35,99,123],"gluconeogenic":[37,101,125],"enzymes.":[38,102],"Moreover,":[39],"apparently":[40],"acting":[41],"via":[42],"conserved":[43],"levels":[44,80],"heightened":[46],"phosphatidylinositol3-kinase":[47],"activity":[48,94],"insulin":[50,53,129,135],"substrate(IRS)-2,":[52],"hepatic":[55,114,119],"a":[59,105],"PKC\u03b9-(i.e.,":[60],"self)-dependent,":[61],"i.e.,":[62],"feed-forward/positive-feedback,":[63],"mechanism.":[64],"In":[65],"contrast,":[66],"Akt2":[67],"activation":[68],"diminished":[70,78,92],"human":[72],"hepatocytes,":[74],"most":[75],"likely":[76],"reflecting":[77],"IRS-1":[79],"activity.":[82],"Treatment":[83],"with":[87],"two":[88],"novel":[89],"PKC-\u03b9/\u03bb":[90,115],"inhibitors":[91],"aPKC":[93],"lipogenic,":[98,122],"Also,":[103],"murine":[106],"obesity/":[107],"model,":[109],"both":[110],"agents":[111],"selectively":[112],"inhibited":[113],"abnormalities":[117],"thereby":[127],"improving":[128],"signalling":[130],"muscle":[132],"adipocytes,":[134],"resistance,":[136],"intolerance,":[138],"hepatosteatosis,":[139],"abdominal":[140],"obesity,":[141],"hypertriglyceridemia":[142],"hypercholesterolemia.":[144]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2549915482","counts_by_year":[],"updated_date":"2026-09-21T07:43:02.447757","created_date":"2016-11-30T00:00:00"}
